Outlook Therapeutics, Inc.
OTLK· Nasdaq
Filed Dec 23, 2021 · 10-K · 84 days after period end · 0001558370-21-017007
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $5.85M | $771.89K |
| Net Income | -$13.40M | -$9.92M | -$10.10M | -$12.20M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Dec 23, 2021 · 84 d after period end